Patent · US Active

Antibodies for Siglec-15 and methods of use thereof

US11390675B2 · kind B2 · utility

0Cited by

183References

3Claims

0Family size

Assignee

NextCure, Inc. · US

Inventors

Linda Liu · Clarksville, US
Benjamin Dallas Flies · Rockville, US
Solomon Langermann · Baltimore, US

Key dates

Filing date	Sep 21, 2017
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Jan 17, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Siglec-15 binding molecules are provides. The molecules are typically an antibody or antigen binding fragment thereof that immunospecifically binds to Siglec-15. Siglec-15 ligand-binding molecules are also provided. The molecules are typically Siglec-15 polypeptide or fusion protein. Methods of using the molecules to reduce Siglec-15 mediated immunosuppression in a subject in need thereof are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.